Published in JAMA on June 28, 2010
The RCT of Acupuncture on PCOS Combined With IR | NCT02491333
Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med (2011) 4.76
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ (2011) 4.05
PPARγ signaling and metabolism: the good, the bad and the future. Nat Med (2013) 3.71
Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol (2011) 3.02
Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2013) 2.15
Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med (2012) 2.13
Cullin-3 regulates vascular smooth muscle function and arterial blood pressure via PPARγ and RhoA/Rho-kinase. Cell Metab (2012) 1.99
Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol (2014) 1.82
5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of ω-3 polyunsaturated fatty acids. Sci Transl Med (2011) 1.63
Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis (2015) 1.62
Differing effects of metformin on glycemic control by race-ethnicity. J Clin Endocrinol Metab (2014) 1.61
Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab (2014) 1.53
Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res (2011) 1.49
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochem Pharmacol (2014) 1.47
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A (2013) 1.45
Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism (2011) 1.41
Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol (2012) 1.40
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2012) 1.22
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol (2011) 1.21
Weight control and prevention of metabolic syndrome by green tea. Pharmacol Res (2010) 1.15
Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care (2013) 1.12
The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc Disord (2014) 1.08
Validity of hospital discharge diagnosis codes for stroke: the Atherosclerosis Risk in Communities Study. Stroke (2014) 1.07
Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity. Am J Physiol Endocrinol Metab (2010) 1.03
Challenges of translating basic research into therapeutics: resveratrol as an example. J Gerontol A Biol Sci Med Sci (2011) 1.03
PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovasc Diabetol (2010) 1.02
Mediterranean diet and cardioprotection: the role of nitrite, polyunsaturated fatty acids, and polyphenols. Nutrition (2011) 1.00
The economics of diabetes prevention. Med Clin North Am (2011) 0.99
Pioglitazone attenuates valvular calcification induced by hypercholesterolemia. Arterioscler Thromb Vasc Biol (2013) 0.99
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am Heart J (2012) 0.98
Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol (2013) 0.98
A call for action: Comparative effectiveness research in asthma. J Allergy Clin Immunol (2010) 0.97
Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery. J Gen Physiol (2011) 0.96
Drug safety crackdown revs up. Nature (2010) 0.96
Mice with cardiac overexpression of peroxisome proliferator-activated receptor γ have impaired repolarization and spontaneous fatal ventricular arrhythmias. Circulation (2011) 0.95
Myocardial insulin resistance induced by high fat feeding in heart failure is associated with preserved contractile function. Am J Physiol Heart Circ Physiol (2010) 0.94
Distinguishing incident and prevalent diabetes in an electronic medical records database. Pharmacoepidemiol Drug Saf (2013) 0.93
Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. J Gen Intern Med (2011) 0.92
Pivotal roles of monocytes/macrophages in stroke. Mediators Inflamm (2013) 0.92
Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations. Diabetes Metab Syndr Obes (2012) 0.91
The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric (2012) 0.91
State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors. J Gen Intern Med (2011) 0.90
Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes. PLoS One (2011) 0.90
Bariatric surgery to unload the stressed heart: a metabolic hypothesis. Am J Physiol Heart Circ Physiol (2012) 0.90
Study of Cardiovascular Health Outcomes in the Era of Claims Data: The Cardiovascular Health Study. Circulation (2015) 0.90
Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States. Contemp Clin Trials (2012) 0.89
Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity. J Med Chem (2012) 0.88
Drug-target network in myocardial infarction reveals multiple side effects of unrelated drugs. Sci Rep (2011) 0.88
Chronic exposure to nicotine enhances insulin sensitivity through α7 nicotinic acetylcholine receptor-STAT3 pathway. PLoS One (2012) 0.88
Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clin Proc (2011) 0.87
Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre-clinical systematic review. J Neurochem (2010) 0.87
Ulcerative colitis: immune function, tissue fibrosis and current therapeutic considerations. Langenbecks Arch Surg (2011) 0.87
Is the cardiovascular system a therapeutic target for cannabidiol? Br J Clin Pharmacol (2013) 0.86
Treatment of risk factors to prevent stroke. Neurotherapeutics (2011) 0.86
Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data. PLoS One (2011) 0.86
Year in review: medication mishaps in the elderly. Am J Geriatr Pharmacother (2011) 0.86
Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors. Pharmacogenomics (2014) 0.85
Development and prevention of postsurgical adhesions in a chimeric mouse model of experimental endometriosis. Fertil Steril (2010) 0.84
Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. BMJ (2016) 0.84
Recent advances in managing and understanding diabetic nephropathy. F1000Res (2016) 0.83
Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. J Am Soc Hypertens (2012) 0.83
Interference with PPARγ in endothelium accelerates angiotensin II-induced endothelial dysfunction. Physiol Genomics (2015) 0.83
The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol (2013) 0.83
Rates, amounts, and determinants of ambulatory blood pressure monitoring claim reimbursements among Medicare beneficiaries. J Am Soc Hypertens (2014) 0.82
Flavonoids as dietary regulators of nuclear receptor activity. Food Funct (2013) 0.82
Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chronic Dis (2014) 0.82
Safety of PPAR agonists. Diabetes Care (2011) 0.82
Evaluating Social Media Networks in Medicines Safety Surveillance: Two Case Studies. Drug Saf (2015) 0.82
PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system? World J Cardiol (2011) 0.82
Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study. Cardiovasc Diabetol (2010) 0.82
After avandia: the use of antidiabetic drugs in patients with heart failure. Tex Heart Inst J (2012) 0.81
Idealized PPARγ-Based Therapies: Lessons from Bench and Bedside. PPAR Res (2012) 0.80
Physiological responses to acute psychological stress are reduced by the PPARγ agonist rosiglitazone. Endocrinology (2012) 0.80
Rosiglitazone use and post-discontinuation glycaemic control in two European countries, 2000-2010. BMJ Open (2013) 0.80
The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges. Br J Pharmacol (2015) 0.80
Long term liver specific glucokinase gene defect induced diabetic cardiomyopathy by up regulating NADPH oxidase and down regulating insulin receptor and p-AMPK. Cardiovasc Diabetol (2014) 0.80
Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice. PLoS One (2012) 0.80
Tight glycemic control and cardiovascular effects in type 2 diabetic patients. Heart Views (2015) 0.79
Rosiglitazone and the case for safety over certainty. JAMA (2010) 0.79
The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals. QJM (2012) 0.79
Glucose control and cardiovascular outcomes: reorienting approach. Front Endocrinol (Lausanne) (2012) 0.79
Insulin sensitizers and heart failure: an engine flooded with fuel. Curr Hypertens Rep (2010) 0.78
Cyclic Stretch Facilitates Myogenesis in C2C12 Myoblasts and Rescues Thiazolidinedione-Inhibited Myotube Formation. Front Bioeng Biotechnol (2016) 0.78
Retinoic acid receptor β2 agonists restore glycaemic control in diabetes and reduce steatosis. Diabetes Obes Metab (2015) 0.78
Validation of methods for assessing cardiovascular disease using electronic health data in a cohort of Veterans with diabetes. Pharmacoepidemiol Drug Saf (2015) 0.78
Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice. J Biol Chem (2015) 0.78
Cardiac ion channel modulation by the hypoglycaemic agent rosiglitazone. Br J Pharmacol (2011) 0.78
Mortality associated with diabetes and cardiovascular disease in older women. PLoS One (2012) 0.78
Diabetes: Breaking news! Rosiglitazone and cardiovascular risk. Nat Rev Cardiol (2010) 0.77
Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. Clin Interv Aging (2010) 0.77
Treating the elderly diabetic patient: special considerations. Diabetes Metab Syndr Obes (2014) 0.77
PPARs: Protectors or Opponents of Myocardial Function? PPAR Res (2015) 0.77
The pleiotropic effects of decanoic acid treatment on mitochondrial function in fibroblasts from patients with complex I deficient Leigh syndrome. J Inherit Metab Dis (2016) 0.77
Deprescribing in Frail Older People: A Randomised Controlled Trial. PLoS One (2016) 0.77
Therapy: What evidence should guide the use of thiazolidinediones? Nat Rev Endocrinol (2010) 0.77
Rethinking cardiac metabolism: metabolic cycles to refuel and rebuild the failing heart. F1000Prime Rep (2014) 0.77
Rosiglitazone protects against severe hemorrhagic shock-induced organ damage in rats. Med Sci Monit (2011) 0.77
Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database. BMC Clin Pharmacol (2011) 0.77
ACP Journal Club. In older patients, rosiglitazone was associated with increased risk for stroke, heart failure, and mortality compared with pioglitazone. Ann Intern Med (2010) 0.76
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf (2005) 2.00
Chart-confirmed guillain-barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009-2010. Am J Epidemiol (2013) 1.46
Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 1.43
Posttransfusion purpura occurrence and potential risk factors among the inpatient US elderly, as recorded in large Medicare databases during 2011 through 2012. Transfusion (2014) 1.40
Nitric oxide levels regulate macrophage commitment to apoptosis or necrosis during pneumococcal infection. FASEB J (2004) 1.33
Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception (2012) 1.20
Use of an active surveillance system by the FDA to observe patterns of quinine sulfate use and adverse hematologic outcomes in CMS Medicare data. Pharmacoepidemiol Drug Saf (2014) 0.98
Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-naive HIV-1-infected US veterans (1992-2004). J Acquir Immune Defic Syndr (2007) 0.96
Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockers. Pharmacoepidemiol Drug Saf (2013) 0.94
Surveillance for Guillain-Barré syndrome after influenza vaccination among the Medicare population, 2009-2010. Am J Public Health (2012) 0.93
Outpatient transfusions and occurrence of serious noninfectious transfusion-related complications among US elderly, 2007-2008: utility of large administrative databases in blood safety research. Transfusion (2012) 0.86
Babesiosis among elderly Medicare beneficiaries, United States, 2006-2008. Emerg Infect Dis (2012) 0.86
Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases. Arthritis Care Res (Hoboken) (2013) 0.85
Transfusion-related acute lung injury and potential risk factors among the inpatient US elderly as recorded in Medicare claims data, during 2007 through 2011. Transfusion (2014) 0.84
Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study. Pharmacoepidemiol Drug Saf (2014) 0.84
Off-label topical calcineurin inhibitor use in children. Pediatrics (2013) 0.83
Candidate metrics for evaluating the impact of prescriber education on the safe use of extended-release/long-acting (ER/LA) opioid analgesics. Pain Med (2014) 0.82
Utilizing Medicare claims data for real‐time drug safety evaluations:is it feasible? Pharmacoepidemiol Drug Saf (2011) 0.79
Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) (2011) 0.78
Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone. Mov Disord (2013) 0.76
Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years. MMWR Morb Mortal Wkly Rep (2017) 0.75
Bleeding events following concurrent use of warfarin and oseltamivir by Medicare beneficiaries. Ann Pharmacother (2013) 0.75